MacroGenics Reports Q2 2025 Financials, Updates Key Strategic Priorities
ByAinvest
Thursday, Aug 14, 2025 4:02 pm ET1min read
MGNX--
MacroGenics reported Q2 2025 financial results, with a cash runway through H1 2027. The company received a $70m upfront payment from Sagard Healthcare Partners under a royalty purchase agreement for ZYNYZ. Newly-appointed CEO Eric Risser outlined key strategic priorities for 2025 and 2026, including determining the development path for lorigerlimab, advancing MGC026 and MGC028 programs, and submitting an IND application for MGC030.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet